BK channel mediated disorders

Patent Pending BK channels are pharmacological targets for the treatment of several medical disorders including stroke[13] and overactive bladder.[14] Although pharmaceutical companies have attempted to develop synthetic molecules targeting BK channels,[15] their efforts have proved largely ineffective. For instance, BMS-204352 (MaxiPost), a molecule developed by Bristol-Myers Squibb, failed to improve clinical outcome in stroke patients compared to placebo.